These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Trastuzumab therapy for the metastatic patient: does the primary match? Leyland-Jones B Ann Oncol; 2002 Jul; 13(7):993-4. PubMed ID: 12176776 [No Abstract] [Full Text] [Related]
7. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab. Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697 [No Abstract] [Full Text] [Related]
8. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer. Kurosumi M Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922 [No Abstract] [Full Text] [Related]
9. The promise of antibody-drug conjugates. Teicher BA; Doroshow JH N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386 [No Abstract] [Full Text] [Related]
10. HER2-positive breast cancer: a new piece of the puzzle. Gnant M; Bartsch R; Steger GG Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817 [No Abstract] [Full Text] [Related]
11. Trastuzumab in breast cancer. Banna GL; Santoro A N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951 [No Abstract] [Full Text] [Related]
13. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers. Reeder-Hayes KE; Carey LA J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811 [No Abstract] [Full Text] [Related]
16. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy. Ellis MJ J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535 [No Abstract] [Full Text] [Related]
17. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A; Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181 [TBL] [Abstract][Full Text] [Related]
18. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales. Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911 [No Abstract] [Full Text] [Related]
19. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer. McArthur HL; Morris PG; Hudis CA J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210 [No Abstract] [Full Text] [Related]